Clinical trials: Primary Raynaud Phenomenon
Raynaud's Phenomenon
Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon
This study represents the first trial to assess the efficacy of oral treprostinil therapy in patients with symptomatic primary or secondary Raynaud's Phenomenon (RP) resistant to vasodilatory therapy.
- Trial name
- NCT02583789
- Testing
- oral treprostinil
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Raynaud's Disease
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048763
- Testing
- Pletal
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Scleroderma, Systemic Sclerosis
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies.
- Trial name
- PSSIT (NCT05098704)
- Testing
- clopidogrel treatment
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Bordeaux
Raynaud's Disease
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow.
- Trial name
- NCT02683408
- Testing
- diosmiplex
- Where
- 11 sites in United States
- Volunteers
- 87 people
- Sponsor
- Primus Pharmaceuticals
Raynaud's Phenomenon Isolated Primary, Raynaud's Phenomenon (Secondary)
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.
The investigators seek to perform a comparative transcriptome analysis of TRP channels residing in the skin between primary and scleroderma secondary Raynaud's phenomenon and healthy subjects.
- Conditions
- Raynaud's Phenomenon Isolated Primary, Raynaud's Phenomenon (Secondary), Healthy
- Trial name
- TRP (NCT03211325)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Primary Raynaud's Phenomeon
Acupressure for the Treatment of Raynaud's Phenomenon
The use of acupressure will be compared to targeted Raynaud's education and will evaluate the' frequency, duration and pain of Raynaud's attacks.
- Trial name
- NCT01784354
- Testing
- Acupressure, Acupressure dilatation, education
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Raynaud Phenomenon
Dermoscopy in Primary Raynaud's Phenomenon
Raynaud's phenomenon (RP) is very frequent in general population (up to 10%). Nailfold capillaroscopy (NFC) is recommended for patients presenting RP, to eliminate systemic disease such as systemic sclerosis.
- Trial name
- VASCUL-R (NCT04644523)
- Testing
- Dermoscopy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Raynaud's Disease, Raynaud Phenomena
Open Label Treprostinil Raynaud's Study
Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed.
- Conditions
- Raynaud's Disease, Raynaud Phenomena, Raynauds
- Trial name
- NCT07112183
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Raynaud Phenomenon, Primary Raynaud Phenomenon
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of…
- Conditions
- Raynaud Phenomenon, Primary Raynaud Phenomenon, Raynaud Disease, Raynaud Syndrome
- Trial name
- NCT03869008
- Testing
- gammaCore Sapphire
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
Primary Raynaud Phenomenon
Cocoa Flavanol Supplementation in Raynaud's Phenomenon
The study aims to investigate the effect that supplementing the diet with cocoa flavanols has on vasospasm symptoms and temperature regulation in women with primary Raynaud's phenomenon (PRP).
- Trial name
- NCT03815162
- Testing
- High Flavanol Cocoa extract, Alkalised cocoa
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR
Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Vasospasm is a transient contraction causing a decrease in caliber of a vessel and thus a decrease in vascularization in a vascular territory leading to suffering of tissue in the sector concerned.
- Conditions
- Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR, Study of Patients and Their Relatives (With or Without Primary PR)
- Trial name
- RAY-GENE (NCT02202291)
- Testing
- Demonstration of genetic mutations causing Raynaud's phenomenon
- Where
- 6 sites in France
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Vasovagal Syndrome VVS, Cardioinhibitory Carotid Sinus Syndrome CSS
POLish Registry of CArdioneuroablation and CArdioneuromodulation
The multicentre observational study POL-CA involves a wide spectrum of patients with a history of syncopy. The study recruits patients with diagnosed vasovagal syndrome, cardioinhibitory carotid sinus syndrome, symptomatic sinus…
- Conditions
- Vasovagal Syndrome VVS, Cardioinhibitory Carotid Sinus Syndrome CSS, Symptomatic Sinus Bradycardia SB or Atrioventricular Block AV, Postural Orthostatic Tachycardia Syndrome POTS
- Trial name
- POL-CA (NCT07196397)
- Testing
- cardioneuroablation, SN sparing hybrid ablation, Cardiac sympathetic denervation
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- SABAMED Medical Center Ltd.